Akero Therapeutics (NASDAQ: AKRO) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating.
Akero Therapeutics, Inc. (AKRO)
Last akero therapeutics, inc. earnings: 3/16 07:30 am
Check Earnings Report
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
AKRO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKRO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKRO alerts
High impacting Akero Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKRO
News
- Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASHGlobeNewswire
- Akero Therapeutics, Inc. (NASDAQ: AKRO) had its price target raised by analysts at Canaccord Genuity Group Inc. from $50.00 to $58.00. They now have a "buy" rating on the stock.MarketBeat
- Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewswire
- Akero Therapeutics, Inc. (NASDAQ: AKRO) was upgraded by analysts at Morgan Stanley from an "equal weight" rating to an "overweight" rating. They now have a $65.00 price target on the stock, up previously from $40.00.MarketBeat
- Akero Therapeutics Appoints Patrick Lamy as Senior Vice President, Commercial StrategyGlobeNewswire
AKRO
Earnings
- 3/17/23 - Beat
AKRO
Sec Filings
- 3/29/23 - Form 8-K
- 3/17/23 - Form S-8
- 3/17/23 - Form 8-K
- AKRO's page on the SEC website